Lung Cancer:综述简读——胸腺肿瘤外科治疗新进展

2018-04-06 萧弈 CardiothoracicSurger

ITMIG领导下通过与区域和社会为基础的兴趣小组合作(ESTS,JART)协作,随着新的胸外科技术的发展,众多关于胸腺手术的历史教条受到了质疑和挑战。因此来自意大利的Enrico Ruffini教授等通过文献回顾,提出目前胸腺肿瘤治疗的外科治疗进展,文章发表在近期的Lung Cancer杂志上。

ITMIG领导下通过与区域和社会为基础的兴趣小组合作(ESTS,JART)协作,随着新的胸外科技术的发展,众多关于胸腺手术的历史教条受到了质疑和挑战。因此来自意大利的Enrico Ruffini教授等通过文献回顾,提出目前胸腺肿瘤治疗的外科治疗进展,文章发表在近期的Lung Cancer杂志上。主要为以下四点:

1. 包括电视辅助胸腔手术(VATS)和机器人辅助胸腔手术(RATS)在内的微创技术(MIT)是早期胸腺肿瘤的标准治疗手段。麻省理工学院的研究证实MIT在术后并发症,局部复发率和生存率方面并不逊色于开放手段。麻省理工学院的研究同时表明MIT在术后住院时间,术中出血量,美容效果方面均优于开放手术。


2. 胸腺肿瘤采用ITMIG/IASLC TNM分期系统,这就需要胸外科手术中根据IASLC/ITMIG淋巴结图谱进行模式转变,包括区域淋巴结的手术管理

3. 有学者提出局限性胸腺切除术的概念,即对于非重症肌无力的I-II期肿瘤患者不接受全胸腺切除术,但目前的结果并不一致。所以,在更成熟的数据发布之前,除了胸腺切除外,一定要遵守现行指南推荐的全胸腺切除术。

4.对于胸膜受累的局部晚期IVa期患者,予以胸膜切除术包括胸膜切除术/剥脱术或胸膜外全肺切除术完全切除病灶,并采用多学科治疗模式,通常具有良好的长期结果。

简单的说,微创手术、淋巴结切除、全胸腺切除(即使是早期胸腺瘤)、胸膜切除(胸膜受累的局部晚期IVa期),这些新概念和技术值得每一位胸外科医生重视。这些治疗策略可以改善胸腺肿瘤患者的预后。

原始出处:
Ruffini E, Filosso PL, Guerrera F, et al. Optimal surgical approach to thymic malignancies: New trends challenging old dogmas. Lung Cancer. 2018 Apr.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663486, encodeId=c4a41663486d5, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Thu Nov 08 21:04:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575671, encodeId=84d415e567151, content=<a href='/topic/show?id=dd78841981a' target=_blank style='color:#2F92EE;'>#胸腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84198, encryptionId=dd78841981a, topicName=胸腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1816139055, createdName=旅苦化文_213, createdTime=Sun Apr 08 12:04:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303401, encodeId=462f30340168, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Apr 07 00:10:17 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303385, encodeId=9eb030338525, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Apr 06 22:45:58 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303373, encodeId=d5733033e369, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Apr 06 21:16:39 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663486, encodeId=c4a41663486d5, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Thu Nov 08 21:04:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575671, encodeId=84d415e567151, content=<a href='/topic/show?id=dd78841981a' target=_blank style='color:#2F92EE;'>#胸腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84198, encryptionId=dd78841981a, topicName=胸腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1816139055, createdName=旅苦化文_213, createdTime=Sun Apr 08 12:04:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303401, encodeId=462f30340168, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Apr 07 00:10:17 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303385, encodeId=9eb030338525, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Apr 06 22:45:58 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303373, encodeId=d5733033e369, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Apr 06 21:16:39 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663486, encodeId=c4a41663486d5, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Thu Nov 08 21:04:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575671, encodeId=84d415e567151, content=<a href='/topic/show?id=dd78841981a' target=_blank style='color:#2F92EE;'>#胸腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84198, encryptionId=dd78841981a, topicName=胸腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1816139055, createdName=旅苦化文_213, createdTime=Sun Apr 08 12:04:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303401, encodeId=462f30340168, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Apr 07 00:10:17 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303385, encodeId=9eb030338525, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Apr 06 22:45:58 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303373, encodeId=d5733033e369, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Apr 06 21:16:39 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-07 飛歌

    厉害了我的哥

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1663486, encodeId=c4a41663486d5, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Thu Nov 08 21:04:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575671, encodeId=84d415e567151, content=<a href='/topic/show?id=dd78841981a' target=_blank style='color:#2F92EE;'>#胸腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84198, encryptionId=dd78841981a, topicName=胸腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1816139055, createdName=旅苦化文_213, createdTime=Sun Apr 08 12:04:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303401, encodeId=462f30340168, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Apr 07 00:10:17 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303385, encodeId=9eb030338525, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Apr 06 22:45:58 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303373, encodeId=d5733033e369, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Apr 06 21:16:39 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1663486, encodeId=c4a41663486d5, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Thu Nov 08 21:04:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575671, encodeId=84d415e567151, content=<a href='/topic/show?id=dd78841981a' target=_blank style='color:#2F92EE;'>#胸腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84198, encryptionId=dd78841981a, topicName=胸腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b1816139055, createdName=旅苦化文_213, createdTime=Sun Apr 08 12:04:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303401, encodeId=462f30340168, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Apr 07 00:10:17 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303385, encodeId=9eb030338525, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Apr 06 22:45:58 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303373, encodeId=d5733033e369, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Apr 06 21:16:39 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

Int Ophthalmol:调节性内斜视研究现状

意大利米兰大学Multimedica眼科诊所的Lembo A近日在Int Ophthalmol发表了他们的一项工作,他们通过仔细研究文献,系统的回顾了调节性内斜视(AE)的研究现状。

胡学强:2017年我国神经免疫学进展

神经免疫性疾病多好发于青壮年,其中一些存在病程迁延,常可出现严重的神经系统症状,甚至遗留神经功能障碍。早期诊断、密切病情监测和及时治疗是改善患者长期预后的关键。2017年,我国神经免疫学领域的专家学者对各种神经免疫性疾病的病因、发病机制、临床特点、诊断与鉴别诊断、治疗策略等方面进行了研究探讨,取得了众多瞩目成就。本文拟就其中一部分重要研究成果进行简要综述。

Nutrients:维生素D补充和非酒精性脂肪肝研究的现状和未来

非酒精性脂肪性肝病(NAFLD)的病理特征为肝细胞中异常累积的甘油三酯,在某些情况下伴有坏死性炎症活动和纤维化(脂肪性肝炎),并可能演变为肝硬化。

Orbit:眼睑刺激性乳头状囊腺瘤:重要的综述!

美国艾伯特爱因斯坦医学院蒙特菲奥雷医学中心眼科与视觉科学系的Tseng MC1和Amin B2及Barmettler A1近日在Orbit杂志上发表了他们近期的一项工作,他们针对乳腺囊腺瘤(SCAP)的现状和治疗进行了文献综述。

JAMA:全新综述——甲状腺结节的诊断和治疗

最新一期(March 6,2018)的JAMA发表了一篇针对甲状腺结节诊疗的综述。该综述在PubMed和Scopus数据库中检索了过去3年来针对甲状腺结节评估和治疗的文献,关注甲状腺结节管理的重要临床问题。

Helicobacter:2017年幽门螺杆菌感染的治疗

本综述总结了2016年4月至2017年4月期间发表的关于幽门螺杆菌(Hp)治疗的重要研究。涉及的主题包括评估铋剂和非铋剂四联疗法疗效的研究。